» Articles » PMID: 21719078

The Effects of an Anti-IL-13 MAb on Cytokine Levels and Nasal Symptoms Following Nasal Allergen Challenge

Overview
Date 2011 Jul 2
PMID 21719078
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: IL-13 is a key T(H)2 cytokine that is implicated in allergic responses.

Objective: We evaluated the effects of an anti-IL-13-blocking antibody compared with placebo on repeated nasal allergen challenge responses in hay fever patients out of season.

Methods: We performed a parallel group double-blind study of anti-IL-13 (single dose, 6 mg/kg intravenously, n = 16) and placebo (n = 15), with an additional open label group given a topical nasal corticosteroid (n = 5). Subjects received intranasal timothy grass pollen (Phleum pratense P5 allergen), and serial samples of nasal mucosal lining fluid were taken by using synthetic absorptive matrix and by nasal lavage.

Results: Administration of anti-IL-13 on day 1 resulted in a significant decrease in IL-13 levels in synthetic absorptive matrix eluates compared with placebo (area under the curve 0-8 hours, change from baseline) during the late phase after nasal allergen challenge on day 5 (P < .05) and day 7 (P < .01). There were no apparent effects of anti-IL-13 treatment on nasal lavage eosinophil numbers or total nasal symptom scores versus placebo. However, in a subgroup with high late-phase IL-13 levels at screening, there was a trend for a decrease in total nasal symptom scores after nasal allergen challenge on day 5, when compared with subjects with low IL-13 levels (P < .10). Nasal fluticasone caused suppression of IL-13 (P < .05 on day 5) as well as IL-5 (P < .01 on day 5) levels in the late phase compared with placebo.

Conclusions: Anti-IL-13 had specific pharmacodynamic action in this nasal allergen challenge model, causing profound inhibition of nasal lining fluid IL-13 responses. In addition, there was a possible effect of anti-IL-13 treatment on total nasal symptom scores in a subgroup with high late-phase nasal IL-13 levels at screening.

Citing Articles

Assessing Human Lung Pharmacokinetics Using Exhaled Breath Particles.

Holz O, Sadiq M, Gress C, Struss N, Stomilovic S, Lundqvist A J Aerosol Med Pulm Drug Deliv. 2024; 38(1):13-17.

PMID: 39636714 PMC: 11844770. DOI: 10.1089/jamp.2024.0032.


Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination.

Mu R, Huang Y, Bouquet J, Yuan J, Kubiak R, Ma E Anal Chem. 2022; 94(43):14835-14845.

PMID: 36269894 PMC: 9631352. DOI: 10.1021/acs.analchem.2c01320.


IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma.

Nur Husna S, Md Shukri N, Mohd Ashari N, Wong K PeerJ. 2022; 10:e13444.

PMID: 35663523 PMC: 9161813. DOI: 10.7717/peerj.13444.


Allergen provocation tests in respiratory research: building on 50 years of experience.

Gauvreau G, Davis B, Scadding G, Boulet L, Bjermer L, Chaker A Eur Respir J. 2022; 60(2).

PMID: 35086834 PMC: 9403392. DOI: 10.1183/13993003.02782-2021.


Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps.

Kariyawasam H, James L, Gane S Drug Des Devel Ther. 2020; 14:1757-1769.

PMID: 32440101 PMC: 7217316. DOI: 10.2147/DDDT.S243053.